Aruna Bio.png
Aruna Bio Announces FDA Clearance of IND for Lead Program AB126, Enabling the First Exosome to Enter in Human Clinical Trials for a Neurological Indication
January 16, 2024 08:00 ET | Aruna Bio
-Phase 1b/2a clinical trial in acute ischemic stroke expected to initiate in 1H 2024- -Marks the first IND for Aruna’s platform with plans to expand AB126, an unmodified exosome derived from...
Aruna Bio.png
Aruna Bio to Participate in the BIO Investor Forum in October 2023
October 10, 2023 08:00 ET | Aruna Bio
BOSTON and ATHENS, Ga., Oct. 10, 2023 (GLOBE NEWSWIRE) -- Aruna Bio, Inc., a leader in the development of neural exosome-based therapeutics for the treatment of neurodegenerative diseases, today...
Aruna Bio.png
Aruna Bio Announces Presentation on the Mechanism of its Neural Exosome Platform and Lead Program, AB126, at the BioProcess International Conference & Exhibition
September 18, 2023 08:02 ET | Aruna Bio
– AB126, an unmodified exosome derived from neural stem cells, shows native therapeutic activity with anti-inflammatory and neuroprotective properties through modulation of the ATP-adenosine axis – ...
Aruna Bio.png
Aruna Bio Announces Preclinical Results from Pilot Study Evaluating AB126 for the Treatment of Amyotrophic Lateral Sclerosis
September 07, 2023 16:05 ET | Aruna Bio
- Data from superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis (ALS) mouse model demonstrated prolonged survival and reduced inflammation in the spinal cord – -AB126, an unmodified exosome...
Aruna Bio.png
Aruna Bio Announces Presentation on Treatment Opportunities for its Neural Exosome Platform and Lead Program, AB126 at the Exosome Based Therapeutic Development Summit
September 05, 2023 16:05 ET | Aruna Bio
- Preclinical data demonstrates AB126, an unmodified exosome derived from neural stem cells, shows native therapeutic activity and evidence of anti-inflammatory and neuroprotective properties – -...
Aruna Bio.png
Aruna Bio Announces Oral Presentation on Treatment Opportunities of Lead Program, AB126 at the Exosome Based Therapeutic Development Summit and Applications of Exosomes BioProcess International Conference & Exhibition
August 15, 2023 08:00 ET | Aruna Bio
BOSTON and ATHENS, Ga., Aug. 15, 2023 (GLOBE NEWSWIRE) -- Aruna Bio, Inc., a leader in the development of neural exosome-based therapeutics for the treatment of neurodegenerative diseases, today...
Aruna Bio.png
Aruna’s Co-Founder and Chief Scientific Officer, Dr. Steven Stice, Receives Entrepreneur Distinction from The University System of Georgia Board of Regents
March 28, 2023 08:00 ET | Aruna Bio
BOSTON and ATHENS, Ga., March 28, 2023 (GLOBE NEWSWIRE) -- Aruna Bio, Inc., a leader in the development of neural exosome-based therapeutics for the treatment of neurodegenerative diseases, today...
Aruna Bio.png
Aruna Bio Announces Appointment of Mike Ryan to its Board of Directors
December 19, 2022 08:00 ET | Aruna Bio
BOSTON and ATHENS, Ga., Dec. 19, 2022 (GLOBE NEWSWIRE) -- Aruna Bio, Inc., a leader in the development of neural exosome-based therapeutics for the treatment of neurodegenerative diseases, today...
Aruna Bio.png
Aruna Bio Announces Presentation on Neural Exosome Treatment Opportunities and Lead Program, AB126 at Exosome Based Therapeutic Development Summit
October 06, 2022 08:00 ET | Aruna Bio
-AB126 is an unmodified exosome derived from neural stem cell lines with the innate ability to cross the blood-brain-barrier- -Preclinical data demonstrate the potential therapeutic activity of AB126...
Aruna Bio.png
Aruna Bio Closes $10.8 Million Common Stock Financing
April 14, 2021 08:00 ET | Aruna Bio
ATHENS, Ga. and RESEARCH TRIANGLE PARK, N.C., April 14, 2021 (GLOBE NEWSWIRE) -- Aruna Bio, Inc., a leader in the development of neural exosomes for the treatment of neurodegenerative diseases,...